1. Home
  2. PHVS vs WOR Comparison

PHVS vs WOR Comparison

Compare PHVS & WOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • WOR
  • Stock Information
  • Founded
  • PHVS 2015
  • WOR 1955
  • Country
  • PHVS Switzerland
  • WOR United States
  • Employees
  • PHVS N/A
  • WOR N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • WOR Aerospace
  • Sector
  • PHVS Health Care
  • WOR Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • WOR Nasdaq
  • Market Cap
  • PHVS 980.3M
  • WOR 3.0B
  • IPO Year
  • PHVS 2021
  • WOR N/A
  • Fundamental
  • Price
  • PHVS $18.60
  • WOR $65.35
  • Analyst Decision
  • PHVS Buy
  • WOR Buy
  • Analyst Count
  • PHVS 6
  • WOR 3
  • Target Price
  • PHVS $37.17
  • WOR $63.67
  • AVG Volume (30 Days)
  • PHVS 35.9K
  • WOR 314.7K
  • Earning Date
  • PHVS 08-13-2025
  • WOR 06-24-2025
  • Dividend Yield
  • PHVS N/A
  • WOR 1.04%
  • EPS Growth
  • PHVS N/A
  • WOR N/A
  • EPS
  • PHVS N/A
  • WOR 1.92
  • Revenue
  • PHVS N/A
  • WOR $1,153,762,000.00
  • Revenue This Year
  • PHVS N/A
  • WOR $3.23
  • Revenue Next Year
  • PHVS N/A
  • WOR $4.45
  • P/E Ratio
  • PHVS N/A
  • WOR $34.04
  • Revenue Growth
  • PHVS N/A
  • WOR N/A
  • 52 Week Low
  • PHVS $11.51
  • WOR $37.88
  • 52 Week High
  • PHVS $25.50
  • WOR $70.91
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 60.00
  • WOR 74.25
  • Support Level
  • PHVS $16.72
  • WOR $57.63
  • Resistance Level
  • PHVS $17.53
  • WOR $64.27
  • Average True Range (ATR)
  • PHVS 0.93
  • WOR 2.03
  • MACD
  • PHVS 0.07
  • WOR 0.40
  • Stochastic Oscillator
  • PHVS 92.86
  • WOR 58.13

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About WOR Worthington Enterprises Inc.

Worthington Enterprises Inc is a designer and manufacturer of products sold to consumers, through retail channels, in the tools, outdoor living and celebrations market categories as well as a wide array of specialized building products that serve customers in the residential and non-residential construction markets, including ceiling suspension systems and light gauge metal framing products, as well as wholly-owned and consolidated operations that produce pressurized containment solutions for heating, cooking and cooling applications, among others. It operates under two reportable operating segments: Consumer Products and Building Products. It derives majority of the revenue from Building Products segment.

Share on Social Networks: